Voyager Therapeutics, Inc. (VYGR)

Market Cap	289.06M +29.0%
Revenue (ttm)	40.37M -49.5%
Net Income	-119.72M
EPS	-2.04
Shares Out	59.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,613,039
Open	5.150
Previous Close	5.000
Day's Range	4.708 - 5.480
52-Week Range	2.645 - 5.550
Beta	1.39
Analysts	Strong Buy
Price Target	17.00 (+250.52%)
Earnings Date	Mar 9, 2026

About VYGR

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company’s lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer’s disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 172
• Stock Exchange: NASDAQ
• Ticker Symbol: VYGR
• Website: https://www.voyagertherapeutics.com

Financial Performance

In 2025, Voyager Therapeutics's revenue was $40.37 million, a decrease of -49.53% compared to the previous year's $80.00 million. Losses were -$119.72 million, 84.2% more than in 2024.

Analyst Summary

According to 6 analysts, the average rating for VYGR stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 250.52% from the latest price.

Price Target

$17.0

(250.52% upside)

Analyst Consensus: Strong Buy